Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea by Novak, Kerri L et al.
 
 
University of Birmingham
Point of Care Ultrasound Accurately Distinguishes
Inflammatory from Noninflammatory Disease in
Patients Presenting with Abdominal Pain and
Diarrhea
Novak, Kerri L; Jacob, Deepti; Kaplan, Gilaad; Boyce, Emma; Ghosh, Subrata; Ma, Irene; Lu,
Cathy; Wilson, Stephanie; Panaccione, Remo
DOI:
10.1155/2016/4023065
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Novak, KL, Jacob, D, Kaplan, G, Boyce, E, Ghosh, S, Ma, I, Lu, C, Wilson, S & Panaccione, R 2016, 'Point of
Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting
with Abdominal Pain and Diarrhea', Canadian Journal of Gastroenterology and Hepatology, vol. 2016, 4023065.
https://doi.org/10.1155/2016/4023065
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Research Article
Point of Care Ultrasound Accurately Distinguishes
Inflammatory from Noninflammatory Disease in Patients
Presenting with Abdominal Pain and Diarrhea
Kerri L. Novak,1 Deepti Jacob,1 Gilaad G. Kaplan,1,2 Emma Boyce,1 Subrata Ghosh,1
Irene Ma,3 Cathy Lu,4 Stephanie Wilson,5 and Remo Panaccione1
1 Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, University of Calgary, Calgary,
AB, Canada T2N 2T9
2Department of Community Health Sciences, Calgary, AB, Canada T2N 2T9
3Division of General Internal Medicine, Calgary, AB, Canada T2N 2T9
4Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada T2N 2T9
5Diagnostic Imaging, University of Calgary, Calgary, AB, Canada T2N 2T9
Correspondence should be addressed to Kerri L. Novak; knovak@ucalgary.ca
Received 24 August 2015; Accepted 29 September 2015
Copyright © 2016 Kerri L. Novak et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Approaches to distinguish inflammatory bowel disease (IBD) from noninflammatory disease that are noninvasive,
accurate, and readily available are desirable. Such approaches may decrease time to diagnosis and better utilize limited endoscopic
resources. The aim of this study was to evaluate the diagnostic accuracy for gastroenterologist performed point of care ultrasound
(POCUS) in the detection of luminal inflammation relative to gold standard ileocolonoscopy.Methods. A prospective, single-center
study was conducted on convenience sample of patients presenting with symptoms of diarrhea and/or abdominal pain. Patients
were offered POCUSprior to having ileocolonoscopy. Sensitivity, specificity, positive predictive value (PPV), andnegative predictive
value (NPV) with 95% confidence intervals (CI), as well as likelihood ratios, were calculated. Results. Fifty-eight patients were
included in this study. The overall sensitivity, specificity, PPV, and NPV were 80%, 97.8%, 88.9%, and 95.7%, respectively, with
positive and negative likelihood ratios (LR) of 36.8 and 0.20. Conclusion. POCUS can accurately be performed at the bedside to
detect transmural inflammation of the intestine. This noninvasive approach may serve to expedite diagnosis, improve allocation of
endoscopic resources, and facilitate initiation of appropriate medical therapy.
1. Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal
(GI) disorder, characterized by chronic abdominal pain and
altered bowel habit, with a benign natural history. With a
worldwide prevalence approximating 10–15%, it is a common
disorder and one of the most frequent sources of referral to
gastroenterology [1].The potential economic burden of IBS is
significant, and some patients have long-term persistence of
symptomswith need formore chronicmanagement strategies
[1–3]. In contrast, the incidence of the inflammatory bowel
disease (IBD) in North America is only a fraction of IBS [4].
A subset of patients with IBS have diarrhea and abdom-
inal pain as predominant symptoms, presenting similarly to
those with inflammatory bowel disease (IBD), thus making
the clinical distinction challenging based on symptoms alone
[5, 6]. Timely differentiation of IBD from IBS is critical
because delay in diagnosis of IBD can increase the risk of
developing complications, hospitalization for management,
and surgery [7].
Clinical indices used to accurately identify inflammation
in patients with symptoms exist but are not discerning for
IBD and have not been incorporated into routine diagnostic
investigation [8]. Laboratory markers are also not always
consistent predictors of inflammation to exclude IBD [9]. For
example, fecal inflammatory markers may exclude inflam-
mation present in the colon but are not always reliable
for small bowel disease common in Crohn’s disease [10].
Hindawi Publishing Corporation
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 4023065, 7 pages
http://dx.doi.org/10.1155/2016/4023065
2 Canadian Journal of Gastroenterology and Hepatology
Endoscopy represents the gold standard diagnostic modality
to investigate symptoms that suggest inflammation. Endo-
scopic resources are limited, however, and the number of
patients with abdominal symptoms diagnosed at endoscopy
with IBD is low [5]. In addition, current guidelines suggest
that many patients should be managed conservatively with
symptom-based diagnosis, given the low yield of traditional
means to detect organic disease [11, 12]. Alternate, noninva-
sive diagnostic strategies such as computed tomography (CT)
andmagnetic resonance imaging (MRI) are not routinely rec-
ommended for the investigation of suspected IBS, yet these
strategies are increasingly used [13]. Screening with these
modalities for inflammation or other worrisome etiology in
IBS should be limited, given the concern over radiation expo-
sure with CT and the high cost and limited access toMRI [13].
Ultrasound (US) is a noninvasive, accurate, safe, effective, and
easily accessible modality. It can be performed in clinic by
gastroenterologists as an extension of the physical examina-
tion [14].
The use of point of care ultrasound (POCUS) for noncar-
diac purposes in medicine by nonradiologists has increased
significantly in the last decade [15]. Focused examination
performed at the bedside during routine clinical assessment
may be used to answer binary diagnostic questions: “does
this patient have free fluid in the abdomen?” [16]. Although
widely implemented as an integral part of routine evaluation
for patients with established IBD inmany parts of Europe, it is
not widely used as a diagnostic tool by gastroenterologists in
North America. The aim of this prospective study of patients
investigated for symptoms to exclude organic disease was to
evaluate the diagnostic accuracy of gastroenterologist per-
formed POCUS in excluding luminal inflammation relative
to gold standard ileocolonoscopy. This tool may be used in
the future to help guide the appropriate use of diagnostic
endoscopy.
2. Materials and Methods
2.1. Patient Population and Study Design. Consecutive
patients presenting for assessment of symptoms including
abdominal pain and diarrhea suspicious for IBD to the
University of Calgary GI clinic were selected for this pilot
study from January 1, 2013, to June 1, 2015. Patients with
significant abdominal obesity (BMI > 40), pregnancy, liver
disease with ascites, or conditions of previously known
luminal inflammation were excluded. Informed consent
was obtained prior to the examination and the study was
approved by the Conjoint Health Research Ethics Board
guidelines.
2.2. Clinical Assessment and POCUS Examination. All
patients underwent a physical examination as per standard
of care. Laboratory inflammatory markers including C-
reactive protein (CRP) were recorded where available, within
2 months of POCUS. Fecal calprotectin was not available
at the time of the study at this center. A gastroenterologist
(KN), with formal training in US of the GI tract and 3-year
experience in the modality, conducted a focused luminal
POCUS examination. A standardized approach was used,
conducting the examination from the left lower quadrant,
examining the colon from the rectum to the cecum, with
examination of the rectum, sigmoid, descending, transverse,
and ascending colon, and cecum. The terminal ileum
was then evaluated, followed by systematic four-quadrant
examination to include the remaining small bowel. All exams
were completed using a Phillips IU22 US machine utilizing
a range of transducers, including high frequency curved
(4–9mHz) and linear probes (12–15mHz).
Presence of inflammatory activity was documented
in binary fashion (“active”/“inactive”). Inflammation was
deemed to be present, as per standard sonographic assess-
ment, if there was increased bowel wall thickness (>3mm for
small bowel, >4mm for large bowel) and the presence of any
additional established indicators of inflammation:mesenteric
inflammatory fat, lymph nodes, and hyperemia or blood flow
as detected on color Doppler imaging [17]. The anatomic
site(s) of disease was also recorded. In addition, complica-
tions including luminal stenoses, penetrating complications
or fistulas, perianal disease, and intra-abdominal abscesses
were described and recorded if present. Finally, commentary
was made regarding echo-stratification or preservation of
wall layers as well as the overall quality of the examination
(adequate/inadequate).
Patients with normal blood work, negative endoscopy,
and histology and who met Rome III criteria for IBS were
identified as having IBS (diarrhea predominant) [18]. Those
with normal endoscopic features were diagnosed withmicro-
scopic colitis, if confirmation was made histologically [19].
Inflammatory bowel disease (IBD) was diagnosed/confirmed
where both endoscopic and histologic markers were present;
in these cases anatomic locations and patterns were recorded.
The gold standard comparator was endoscopy alone for all
studies. Finally, alternate etiologies including segmental col-
itis associated with diverticula, infectious, or ischemic colitis
were also recorded.
2.3. Endoscopic and Histologic Examination. All patients
underwent ileocolonoscopy after POCUS. The time interval
to routine or expedited endoscopy, determined based on
clinical suspicion of disease, was recorded. Extent of the
endoscopy was recorded including intubation of the terminal
ileum or lack of as well as the presence of disease activity,
which was recorded in a binary fashion (present/absent),
along with documentation of the etiology of the inflamma-
tion (confirmation of Crohn’s disease or ulcerative colitis or
other suspected etiology) and, if present, the anatomic loca-
tion. Where clinically indicated, biopsies were taken in both
the small and large bowel and results (presence/absence of
inflammation)were recorded. If biopsies were taken as part of
the standard evaluation, this too was recorded as confirma-
tion of organic disease or its absence.
2.4. Patient Satisfaction. A subset of patients (14/58) com-
pleted a 12-question patient satisfaction questionnaire, with
graded responses following the POCUS examination in
clinic. The questionnaire evaluated patient satisfaction with
the overall experience, patient perception of the value of
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Table 1: Patient demographic and laboratory investigation data
(change title).
𝑛 (%)
Gender
Male 19 (33)
Female 39 (67)
Median age (years) 32.8 (17.8–72.4)
Median CRP (mmL, range) (𝑛 = 31)∗ 3.4 (0.6–36.7)
Median time between POCUS and CRP
(days) 39.7 (0–127)
Median time from POCUS to endoscopy
(days, range) 30 (0–149)
Adequate POCUS exam quality 56 (96.5)
TI intubation on endoscopy 56 (96.6)
∗Only a subset had CRP measured that is the 𝑛 = 31.
POCUS, and the willingness to incorporate POCUS as an
extension of the physical examination in clinic.
2.5. Statistical Analysis. Demographic data and ultrasound
quality were evaluated using descriptive statistics. Further
analysis was aimed at evaluating the ability of POCUS to
detect inflammation in symptomatic patients compared with
standard colonoscopy; again, colonoscopy was considered
the gold standard. Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and the posi-
tive and negative likelihood ratios (LR) with 95% confidence
intervals (CI) were calculated for the overall POCUS score,
compared to endoscopy only. To further evaluate POCUS, the
above-mentioned statistics were stratified for segmental anal-
ysis, either ileum or colon. Accuracy of the detection of dis-
ease location, if present, was also evaluated. In caseswhere the
ileum was not seen in endoscopic examinations, correlations
were made between the endoscopic and US segments of the
colon alone. Finally, the ultrasound examination quality was
measured descriptively. Histology was reported; however, it
was not used as the gold standard.
3. Results
A total of 58 patients presenting to the clinic with symptoms
were included. Demographic details are presented in Table 1.
Two patients with a high BMI (>35) contributed to poor exam
quality; however, the bowel was visualized; thus, they were
included in the analysis. The remaining 56/58 (96%) exam-
inations were of good quality. Endoscopies were performed
following POCUS with a median of 30 days and all were
included in the analysis. All but 2 examinations intubated the
terminal ileum (Table 1).
Inflammatory activity was detected sonographically (pos-
itive study) in 9/58 (15.5%) ranging from mild to severe
inflammation (Tables 2 and 3). Mesenteric lymph nodes and
increased bowel wall thickness were the most common US
parameters identified and were seen in all patients with US
activity (9/9 100%) (Figure 1). The only complication identi-
fied was a stricture, present in 1/9 cases (11%), characterized
Table 2: Descriptive ultrasonographic and endoscopic data.
Ultrasound
𝑁 (%)
Active inflammation on US 9/58 (15.5)
Increased bowel wall thickness 9/9 (100)
Lymph nodes 9 (100)
Inflammatory fat 7 (78)
Hyperemia 3 (33)
Preserved wall layers 10 (100)
Complications+ 1 (11%)
Active site on endoscopy (𝑛 = 10)
Ileum 4 (40%)
Colon 5 (50)
Ileocolonic 1 (10%)
+
Complications identified include any of abscess, stricture, phlegmon, or
inflammatory mass.
Table 3: A 2 × 2 table for ultrasound compared to gold standard
endoscopy.
Positive endoscopy Negative endoscopy
Positive US 8 2
Negative US 1 47
Table 4: Sensitivity, specificity, PPV, and NPV of POCUS relative to
endoscopy.
Overall Ileum Colon
Sensitivity%
(CI%)
80.0
(44.4–97.5)
100.0
(47.8–100.0)
60.0
(914.7–94.7)
Specificity%
(CI%)
97.8
(88.5–99.9)
98.2
(90.45–99.9)
100.0
(93.3–100.0)
PPV%
(CI%)
88.9
(51.7–99.7)
83.3
(35.9–99.6)
100.0
(29.2–100.0)
NPV%
(CI%)
95.7
(85.5–99.5)
100.0
(93.5–100.0)
96.36
(87.5–99.6)
Positive LR
(CI%)
36.8
(5.2–262.1)
56.0
(8.0–390.6)
—
(—)
Negative LR
(CI%)
0.20
(0.06–0.71)
—
(—)
0.40
(0.14–1.17)
by fixed luminal apposition and narrowing, with evidence of
proximal small bowel dilation. Ten (10/58 or 17%) patients
had inflammation confirmed on endoscopy (Tables 3 and 4).
Most patients (93%) had biopsies and pathology completed,
and all 10 had inflammation confirmed histologically. Of
these, 4/10 (40%) had ileal CD (Figure 1), 1 with ileocolonic
distribution of inflammation, 5 had colonic inflammation (1
with a new diagnosis of ulcerative colitis, 1 with segmental
diverticular inflammation, and the remaining 3 had patchy,
mild colonic inflammation consistent with colonic CD).
There was one false-positive US exam, with 2 false-negative
findings (see 2 × 2 data in Table 3). In addition, 9 patients
with normal colons both sonographically and endoscopically
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Figure 1: First suggestion of terminal ileal Crohn’s disease identified
on sonography, with thickened distal ileum running over the
hypoechoic iliac artery.Thewhite linemarks the thickened ileal wall
with echogenic or white air in the lumen.
Figure 2: Normal sigmoid colon with normal haustral folds (white
arrow).
revealedmicroscopic colitis on pathology. One patient exhib-
ited no evidence of disease endoscopically nor on US but
had mild inflammatory activity identified histologically in
the ileum, suggesting possibly early IBD. All other cases con-
firmed diarrhea-predominant IBS (38/58 65.5%) (Figure 2).
There were no cases of ulcerative colitis identified in this
study. In those patients with a positive POCUS, endoscopic
exams occurred with shorter intervals with a median of days.
The shortest wait time for endoscopy after US was endoscopy
on the same day of the US exam.
POCUS exhibited a PPV of 88.9% (95% CI: 51.75–
99.72) and a NPV of 95.7% (95% CI: 85.5–99.5). The overall
sensitivity and specificity of POCUSwere 80% (95%CI: 44.4–
97.5) and 97.8% (95% CI: 88.5–99.9), respectively, using a
cutoff for bowel wall thickness of 3mm for the ileum and
4mm for the colon, with positive andnegative LRs of 36.8 and
0.20 (Table 3). When the results were analyzed by segment,
comparing colonic disease and ileal disease separately, ultra-
sound detection of ileal disease exhibited higher sensitivity
compared to the colon compared to gold standard endoscopy
(Table 3).
Of the 10 patients with confirmed inflammatory activity
on endoscopy, all had CRP (7/10 within 1 month) completed,
and 5 were elevated while the other 5 were within normal
range. The median CRP value for these 10 patients was
6.9mg/L. In those with elevated CRP, none of the US exam-
ination, confirmed endoscopically, revealed severe disease
while all those 3 cases with moderate to severe sonographic
disease activity had CRP within normal range, measured
within 40 d of the US.
All 14 patients who completed questionnaires described
the preparation for US as “easy” and reported an increased
understanding of their disease and disease location following
the exam. All of these patients believed POCUS had value in
guiding disease management and found the increased clinic
time acceptable and beneficial to their health.
4. Discussion
To our knowledge, this is the first prospective study to evalu-
ate the accuracy of gastroenterologist-performed POCUS in
excluding inflammation in symptomatic patients compared
to colonoscopy in North America. The accuracy established
here is similar to previous published data [20–22]. There is
a significant need for noninvasive, safe, resource-conscious
modalities of accurately detecting inflammation in symp-
tomatic patients, as symptoms alone do not accurately reflect
inflammatory disease activity and incorrect diagnosis can
delay appropriate management of IBD [23, 24]. Ultrasound
has been shown to significantly impact clinical decisions,
when used at the bedside [25]. Symptoms of diarrhea and
abdominal pain are common as manifestations of irritable
bowel syndrome, and diarrhea is a symptom that often drives
patient visits to primary care [1, 21]. Commonly used non-
invasive markers such as C-reactive protein (CRP) may be
falsely negative and fecal calprotectin has variable availability
and may have a lower accuracy in detecting small bowel
inflammation [9, 26].
The rate of pathologically proven histologic inflammation
in this study, either microscopic colitis or inflammatory
bowel disease, was 20/58 (34%). This figure is much higher
than that quoted for larger populations of patients with IBS
including all subtypes of IBD. Given their symptoms, this
population was identified as “high risk” and in need of
ileocolonoscopy as part of standard of care investigation and
the high pathology rate likely reflects some bias or overrepre-
sentation of pathology, given the convenience sampling from
the “high-risk IBD” clinic. However, gold standard evaluation
with endoscopy is not always indicated in IBS patients, as it is
resource intensive and carries the associated risks of an inva-
sive examination (including patient tolerance) [12, 22]. Tools
to support indication for endoscopy would be helpful, in
addition to the timing/urgency of endoscopy. In this study,
83% (48/58) of patients had no evidence of inflammation
on POCUS or endoscopy, suggesting that ultrasound may
obviate the need for endoscopy in select patients, especially
in combination with a low CRP, as recent evidence suggests
that CRP < 1.0 makes the probability of IBD very low [9].
Clinical factors suggesting organic etiology including MC
may also be useful, such as night time stooling, weight loss,
and age greater than 50 years [27]. In this study, CRP was not
suggestive of more severe disease either sonographically or
endoscopically, illustrating, even in this small sample, limita-
tions with using CRP as a guide for the need for endoscopy.
Given current wait-times for nonurgent endoscopy, inappro-
priate delays may result as a consequence of false-negative
results of currently available tests [24]. Thus, a widely
available, accurate set of clinical tools that would include
noninvasive US may guide the appropriate use of diagnostic
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endoscopy. This has been demonstrated here with the high
likelihood ratio of US, suggesting a very high probability of
confirming IBD with a positive scan [28]. This may allow
for confident expedition of urgent diagnostic assessment
and early appropriate therapy. Here, abnormal US findings
resulted in expedited endoscopy with median time to diag-
nosis of 26 days in those with active IBD on sonography,
compared to a median time to endoscopy of 30 days for the
study population.
The accuracy of detecting disease in the terminal ileum
on cross-sectional imaging tends to be greater compared to
the colon, as was exhibited in this study on US [14]. The sen-
sitivity and specificity for detecting ileal disease was higher
compared to colonic disease (Table 4). Both cases (2/10)
missed on US were mild endoscopically, possibly not yet
exhibiting cross-sectional disease activity [29]. Regardless of
imaging modality, mild disease is difficult to detect, given the
absence of transmural involvement, as early disease involves
themucosa and this is also reflected here, as there were 2 false
negatives versus only 1 false positive (Table 3). This circum-
stancemay be best served by the addition of fecal calprotectin,
valuable for detecting inflammation in this context [9].
Although a normal US may not obviate the need for endo-
scopic confirmation, it was however reassuring and suggested
a need for a less urgent endoscopy as any disease missed
was most likely relatively mild. There were no cases where
the distal terminal ileum was normal on endoscopy and
disease was isolated to the proximal small bowel, as has been
reported in up to 30% of cases with small bowel involvement
[30]; however, in 2 patients with both US and endoscopic
activity (true positives), there was an estimation between 25
and 30 cm of active disease proximal to that region examined
endoscopically.Thus, US also provided insight into the length
or burden of the disease [31]. One case exhibited negative
US and negative endoscopy, yet mild inflammatory activity
on pathology. This may indicate early inflammatory bowel
disease, an important etiology to detect early in order to alter
the natural disease history. This again highlights the need
for concomitant clinical tools such as stool and serum-based
inflammatory markers, combined with clinical factors, to
direct appropriateness of endoscopic evaluation and biopsies.
Nine patients with both negative US and endoscopy had
microscopic colitis (MC) confirmed histologically. Five of
these patients (55%) exhibited extensive small bowel fluid
filled loops, a novel finding suggesting possible pathology of
the small bowel as well (Figure 2). This requires investigation
and confirmation with larger numbers. Small bowel involve-
ment in MC is not well understood and may be missed on
endoscopy because the small bowel may not be extensively
visualized or biopsied. Thus, POCUS may also contribute
significant understanding of anatomy and function in regions
of the bowel not seen endoscopically.
Image quality has been suggested to be more variable
in US compared to MR or CT, potentially limiting US in
some populations, specifically in those with high BMI (>35)
with increased abdominal wall adiposity. Only 2 patients
in this study had poor quality examinations due to high
BMI; however, the US examinations were still deemed suf-
ficient. There are no currently existing training guidelines
for gastroenterologists to guide minimal requirement for
competency in luminal sonography in Canada, given the
evolution of this emerging modality in the field. However,
it is a standard part of training in many European countries
including Germany and Italy, where at least 100 examinations
are recommended [32]. Inexperienced sonographers have
also shown to have significant ability to accurately detect
disease [33].
Patient engagement and satisfaction are important com-
ponents of establishing rapport and trust and are crucial for
long-term success in the management of both chronic func-
tional disorders and inflammatory conditions. US improved
patient understanding and was well tolerated and was gen-
erally preferred over invasive endoscopy.This tool may prove
to be important in facilitating understanding and reassurance
for patients at diagnosis and is a radiation-free and relatively
inexpensive modality that can be used serially for disease
monitoring in established IBD. The sample reflecting patient
satisfaction was however small, in this early pilot study.
There are a number of limitations in this study, as it
is small and is limited to one academic center with one
sonographer performing bedside US examinations. These
limitations should of course be kept in mind when consider-
ing the generalizability of this study to other centers. This is,
however, a novel modality in gastroenterology, and training
guidelines along with reporting and quality frameworksmust
be established. In addition, this preliminary analysis is under-
powered; therefore, a single error, false-positive or negative,
will significantly adversely impact the sensitivity and speci-
ficity in this small sample.Thus, prospectively collected larger
studies are necessary to understand accuracy of the modality
with and without additional clinical factors such as clinical
predictors and inflammatory markers.
The time interval betweenUS and endoscopywas variable
with few endoscopic examinations completed more than 3
months after the POCUS.This likely reflects real life practice,
however, as these patients were clinically suspected to have
IBS and investigation for most of them was triaged as
nonurgent. There were no medical interventions initiated
for any patients; therefore, no structural changes should
result between imaging and endoscopic evaluations. Finally,
the sonographer in this study was also performing ileo-
colonoscopy, not blinded to the US results, which may bias
the commentary on endoscopy. In order to minimize this
bias, nearly all (94%) had biopsies taken to definitively
exclude unrecognized inflammation.
5. Conclusion
Point of care US is a safe, noninvasive means of accurately
detecting inflammation in patients being investigated for
symptoms of diarrhea and abdominal pain. It is timely, as
it occurs at the bedside during clinical assessment. It is well
accepted by patients and can be employed to further direct
definitive diagnosis and management and possibly obviate
the need for endoscopic evaluation in certain cases. Given the
high positive likelihood ratio with a positive exam, it can be
effectively used as a triage tool to expedite endoscopy.
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